TACE Plus Stereotactic Body Radiation Therapy (SBRT) for Liver Cancer
This trial is testing whether adding a specialized radiation treatment to the standard chemotherapy treatment for liver cancer will help control the cancer better.
- Liver Cancer
2 Primary · 13 Secondary · Reporting Duration: 5 years
2 Treatment Groups
TACE Plus Stereotactic Body Radiation Therapy (SBRT)
1 of 2
Transarterial Chemoembolization (TACE)
1 of 2
128 Total Participants · 2 Treatment Groups
Primary Treatment: TACE Plus Stereotactic Body Radiation Therapy (SBRT) · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 26 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What are doctors and researchers hoping to study and discover through this clinical trial?
"The success of this clinical trial will be judged by the patients' Overall Survival rates, which will be measured before treatment, 1 month, 3 months, and then every 3 months up to 2 years. Additionally, the Radiation Therapy Classic Radiation Toxicity Assessment (defined as Classic RILD), the Response Rate (defined as Modified RECIST), and the Radiation Therapy Overall Toxicity Assessment (defined as CTC V4.0) will be secondary measures of success." - Anonymous Online Contributor
How many individuals are partaking in this clinical trial?
"The trial is ongoing and is currently looking for 128 patients at a single site, according to the listing on clinicaltrials.gov. This particular study was first posted on 5/27/2019, with the most recent update on 11/10/2021." - Anonymous Online Contributor
Does the FDA recognize TACE Plus Stereotactic Body Radiation Therapy (SBRT) as an effective treatment?
"TACE Plus Stereotactic Body Radiation Therapy (SBRT) is estimated to be a 3 on a scale of 1 to 3 in terms of safety." - Anonymous Online Contributor